Poor
Not Aligned
Patient Risk:
Low
Summary
Most statements evaluate patent/generic launch timing and do not appear in the provided FDA prescribing information excerpts; therefore, label alignment cannot be supported and several content areas (e.g., approved indications/dosing/safety) are not actually addressed by these statements.
Category Scores
Accurate Statements
Provigil is the brand name for modafinil.
Not explicitly stated in the provided label excerpts.
Generic availability can depend on remaining secondary patents (for formulations, polymorphs, delivery systems, or dosing regimens) that still block approval.
Not supported or addressed in the provided FDA prescribing information excerpts.
Unsupported Statements
Patent expiration is the point when competitors can rely on the original drug’s active-ingredient IP without a patent infringement risk.
Not addressed in the provided FDA label excerpts.
Generic availability can depend on remaining secondary patents (for formulations, polymorphs, delivery systems, or dosing regimens) that still block approval.
Not addressed in the provided FDA label excerpts.
In mapping “when generics can launch,” relevant end dates may include the last drug substance patent, any formulation/polymorph or method-of-use patents still in force, and regulatory exclusivity that can extend effective marketing protection even after some patents end.
Not addressed in the provided FDA label excerpts.
Provigil-specific patents may remain in force even if core protection is no longer the primary barrier in most markets.
Not addressed in the provided FDA label excerpts.
Additional “evergreen” patents can affect how certain versions enter or how they’re labeled, even when generic modafinil is widely marketed.
Not addressed in the provided FDA label excerpts.
The fact that modafinil generics exist indicates that the core protection for modafinil is no longer acting as the primary barrier in most markets.
Not addressed in the provided FDA label excerpts.
Generic launch timing can hinge on patent expiry, regulatory exclusivity, patent litigation/settlement, and regulatory labeling/design triggers.
Not addressed in the provided FDA label excerpts.
Patent expiry is the date when a listed patent term ends.
Not addressed in the provided FDA label excerpts.
Regulatory exclusivity is non-patent legal protection (when applicable) that can delay approval or marketing.
Not addressed in the provided FDA label excerpts.
Patent litigation/settlement can set a launch date even before every patent formally expires.
Not addressed in the provided FDA label excerpts.
Label wording or specific indications can lag even if approval is possible.
Not addressed in the provided FDA label excerpts.
The same brand can have different “effective” end dates depending on which event actually blocks generic marketing.
Not addressed in the provided FDA label excerpts.
A precise answer about how long provigil exclusivity lasts for generics in the U.S. depends on the specific Provigil/New Drug Application (NDA) reference and which exclusivity category applies, plus the active patent set at the time.
Not addressed in the provided FDA label excerpts.
To determine exclusivity timing, the latest patent/exclusivity events for the Provigil listing must be checked and the last barrier identified (often the last relevant expiration date across the patent family).
Not addressed in the provided FDA label excerpts.
Patent and exclusivity timelines vary by country.
Not addressed in the provided FDA label excerpts.
Generic marketing timing and approval timing can differ depending on the country and on whether “when generics can be marketed” or “when approvals can happen” is being considered.
Not addressed in the provided FDA label excerpts.
Contradictions
Important Omissions
No substantive prescribing-information evaluation of PROVIGIL was provided (e.g., approved indications, dosing/administration, contraindications, warnings/precautions, drug interactions, or specific population use) relative to the FDA label excerpts supplied.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The supplied statements are largely about patent/exclusivity and generic launch timing and do not directly describe medication dosing, contraindications, warnings, or patient-management instructions from the label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Most statements are about patent/exclusivity/generic launch timing, which is not addressed in the provided FDA prescribing information excerpts; therefore, they cannot be verified for label alignment.
Suggested Improvement
Evaluate and state only claims that are explicitly supported by the provided FDA label sections (e.g., indication, dosing, contraindications, warnings/precautions, interactions, and specific populations), or provide the exact FDA label text relevant to any patent/exclusivity claim.